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SINTESIS NANOPARTIKEL BISMUT OKSIDA UNTUK APLIKASI 
RADIOTERAPI 
ABSTRAK 
 
 Nombor atom tinggi (Z) nanopartikel bismut oksida (Bi2O3 NPs) mempunyai 
penembusan sel yang lebih banyak dan kurang kesan buruk daripada pemeka sinaran 
konvensional. Pelbagai saiz Bi2O3 NPs telah berjaya dihasilkan dengan menggunakan 
kaedah hidroterma dan digunakan untuk aplikasi radioterapi. Beberapa sintesis 
parameter telah dikaji: kesan perbezaan suhu dan kesan perbezaan masa hidroterma, 
kesan perbezaan kepekatan bismuth nitrat, Bi(NO3)3, dan, kesan perbezaan kepekatan 
polietilena glikol (PEG). Sifat-sifat Bi2O3 NPs telah dikaji untuk menentukan 
kehadiran fasa, penghabluran, morfologi, kehadiran unsur dan saiz partikel. Analisa 
XRD membuktikan Bi2O3 tulen dengan fasa monoklinik telah dihasilkan (Kod 
Rujukan ICDD: 98-000-6260). Saiz Bi2O3 NPs didapati meningkat dengan 
peningkatan suhu dan masa tindakbalas hidrotherma. Walaubagaimanapun, apabila 
kepekatan Bi(NO3)3 meningkat, saiz partikel Bi2O3 NPs menurun disebabkan oleh 
kurangnya resapan ion ke dalam nucleus. Pemerhatian terhadap morphologi 
menunjukkan Bi2O3 NPs berbentuk rod. Nanopartikel yang disalut dengan  PEG tidak 
menunjukkan sebarang peningkatan saiz. Berdasarkan analisa FTIR, keamatan Bi2O3 
NPs berkurang apabila kepekatan PEG meningkat kerana molekul PEG dapat diserap 
ke permukaan kristal Bi melalui ikatan Bi–O. Bi2O3 NPs yang dihasilkan kemudiannya 
menjalani kajian ketoksikan dan radioterapi. Kajian ketoksikan terhadap Bi2O3 NPs 
tidak memberi kesan toksik kepada sel barah payudara (mcf-7) pada kepekatan 0.05 
µM - 50 µM. Prestasi radioterapi oleh Bi2O3 NPs yang telah dihasilkan diperoleh 
dengan mengira nisbah peningkatan pemekaan (SER). Akhirnya, 60 nm Bi2O3 NPs 
diperolehi sebagai keputusan yang optimum dengan SER 1.26. 
xxi 
 
SYNTHESIS OF BISMUTH OXIDE NANOPARTICLES FOR 
RADIOTHERAPY APPLICATION 
ABSTRACT 
 
 High atomic number (Z) of bismuth oxide nanoparticles (Bi2O3 NPs) has more 
cell penetration and less adverse effects than conventional radiosensitisers. In this 
work, various sizes of Bi2O3 NPs were successfully synthesised using hydrothermal 
method. Several synthesis parameters were studied: effect of hydrothermal reaction 
temperature, effect of hydrothermal reaction time, effect of bismuth nitrate, Bi(NO3)3 
concentration and effect of polyethylene glycol (PEG) concentration. The properties 
of Bi2O3 NPs were then characterised to determine the phase presence, crystallinity, 
morphology, elemental presence and size of nanoparticles. The as-synthesised Bi2O3 
NPs was in monoclinic Bi2O3 phase (ICDD 98-008-5622). Increasing reaction 
temperature and time increased the size of Bi2O3 NPs. However, as the Bi(NO3)3 
concentration increased, the particle size of Bi2O3 NPs decreased due to less ions 
diffusion per nuclei. The morphology observation showed that Bi2O3 NPs were in rods 
form. Coating with PEG did not show any increase in nanoparticles size. Based on 
Fourier-transform infrared spectroscopy (FTIR) analysis, by increasing the PEG 
concentration, the intensity of Bi2O3 NPs band diminished because PEG molecules 
could adsorb onto the surface of Bi crystals through Bi–O bonding. After that, the 
produced Bi2O3 NPs were subjected to cytotoxicity analysis and radiotherapy.  Bi2O3 
NPs did not induce cytotoxicity in breast cancer (mcf-7) cell lines at concentration 
from 0.05 µM to 50 µM. The radiotherapy performance of the as-prepared Bi2O3 NPs 
was obtained by calculating the sensitisation enhancement ratio (SER). The optimum 
result was obtained for 60 nm Bi2O3 NPs with SER of 1.26.
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Research background 
 
 Nanomaterials with diameters ranging between 1 and 100 nanometers, are 
natural bridges between molecules and extended solids. Nanomaterials are complex of 
many-electron systems, where reduced sizes and quantum confinement of electrons 
and phonons give birth to fascinating new effects, potentially tunable with particle size 
(Van Dijk et al., 2005). The use of nanomaterials in medical application has been 
developed into a promising research area known as nanobiotechnology (Ahmed et al., 
2012). The application of nanomaterials in medical field is very much welcomed 
nowadays especially in biological labelling and sensing, and cancer therapy. The main 
advantage of using nanomaterials is that its properties can be tuned or manipulated in 
order to meet the specific requirements of particular applications (Sumer and Gao, 
2008). 
 Recently, application of nanomaterials in cancer therapy has gained a great 
interest. One of the main modalities for the treatment of cancer is radiotherapy. 
Radiotherapy is a critical component of the modern approach for curative and adjuvant 
treatment of cancers. Radiotherapy controls the growth of cancerous cells by 
bombardment with ionizing radiation, causing deoxyribonucleic acid (DNA) damage 
by direct ionization or through generation of free radicals by ionization of water or 
oxygen molecules. Sufficient damage to DNA can halt cell growth and prevent 
metastasis. The primary drawback is collateral damage: there is little distinction in 
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absorption between healthy and malignant tissues, and thus doses must be limited in 
order to mitigate unwanted damage to the tumour surroundings (Cooper et al., 2014).  
 Nanomaterials with high atomic number (Z), have recently received wide 
interests for their excellent radiosensitisation effect in order to overcome the 
weaknesses, as well as to selectively increase the radioactivity deposition in the cancer 
region (Kaur et al., 2013, Xiao et al., 2011). The strong photoelectric absorbance 
capacities and the numerous short-range secondary electrons generated on the particle 
surface can accelerate the DNA break and thus kill more tumour cells when undergo 
the radiotherapy. Meanwhile, nanoparticles down to 100 nm in diameter could increase 
tumour accumulation in the intravenous administration by virtue of the enhanced 
permeability and retention (EPR) effect of leaky tumour vasculature. Thus, it is 
believed that the nanometer size radiosensitiser could efficiently integrate the 
radiosensitisation effect as well as showing a great potential in delivering sufficient 
radiation dosage to the targeted tumour. 
 Gold nanoparticles (AuNPs) (Z = 79) is the most well developed nanoparticle 
platform. Hainfeld et al. (2013) reported that gold nanoparticles (AuNPs) (Z = 79) 
showed high-resolution CT-scan when AuNPs was injected into mice and evidently 
increased approximately three times local radiation dose in radiotherapy. The AuNPs 
was found to be effective as radiosensitiser to kill tumour cell by surrounded or loaded 
to specific cancer cells. However, the high cost of gold could limit the widespread use 
of AuNPs. The cost of 1kg bismuth is around USD29, while 1kg gold is around USD39 
000  (Argus 2018, Goldprice 2018). Bismuth nanoparticles (BiNPs) (Z = 83), is a cost 
effective alternative and a better candidate for high Z radiosensitiser research. 
Furthermore, bismuth compounds are biodegradable and biocompatible with a long 
history in biomedicine. To date, most investigations centering on the use of bismuth 
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for nanoparticulate radiosensitiser. However, comprehensive cytotoxicity information 
of BiNPs is not available. BiNPs was detected in the nervous system and other organs 
of the mice (Stoltenberg et al., 2003). Therefore, the approval of Bi as a non-toxic 
alternative to Pb has been questioned by scientists who raised concerns about the lack 
of knowledge about Bi toxicity. 
 Bismuth-based nanoparticles have been studied as radiosensitiser. For 
example, bismuth sulphide nanoparticles (Bi2S3 NPs) could be successfully realized 
on the tumour-bearing mice model in the X-ray radiotherapy research, resulting in 
significantly higher inhibition effect for the tumour growth (Yao et al., 2014). Bismuth 
selenide nanoparticles (Bi2Se3) had exhibited remarkably enhanced DNA damage 
suggesting the strong radiotherapy enhancement effect of Bi-based nanoparticles 
(Song et al., 2015). Most recently, bismuth oxide nanoparticles (Bi2O3 NPs) also has 
be used to kill tumour in radiotherapy. Bi2O3 NPs also has been used in many medical 
and cosmetic applications for many years (Kim et al., 2008). Stewart et al. (2014) 
showed that Bi2O3 NPs could be tailored with different oxygen contents to induce cell 
proliferation or toxicity. Another research highlighted that a theranostic system based 
on Bi2O3 NPs would be highly effective in the treatment of cancer (Bogusz et al., 
2014). Thus, it is suggested that Bi2O3 NPs is an ideal alternative to evaluate the 
therapeutic effect of nanomedicine based radiosensitiser in the radiotherapy research. 
Therefore, several approaches have been employed to synthesis Bi2O3 NPs in 
materials science and engineering. Bi2O3 NPs has been synthesised via sol gel method 
(Armelao et al., 1998, Xiaohong et al., 2007), citrate gel process (Anilkumar et al., 
2005), oxidation of bismuth metal at 800 °C or thermal decomposition of bismuth salt 
solution (Krüger et al., 2000, Davidge, 1986), flame spray pyrolysis (Mädler and 
Pratsinis, 2002), polyol method (Jungk and Feldmann, 2001) and atomic-pressure 
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chemical vapor deposition (CVD) (Shen et al., 2007). Although these methods have 
been proven to be successful in the synthesis of Bi2O3 NPs, they normally require high 
temperature heat treatment, long synthesis period, and post treatment, which is far 
from low cost and apparently require sophisticated equipments. Hence, a more simple 
synthesis method, which is precipitant-free, additive-free, and low cost, is sought after 
for the synthesis of  Bi2O3 NPs. A hydrothermal method is a powerful method in 
synthesis of Bi2O3 NPs at a considerably low temperature, energy saving and cost 
effective benefits (Wu et al., 2011). The hydrothermal method also has the advantages 
such as controllable particle size, morphology and the degree of crystallinity by simply 
changing the experimental parameters (Xu et al., 2005). Table 1.1 shows in detail the 
comparison of several approaches to produce Bi2O3 NPs. 
 
Table 1.1: The comparison of several approaches to produce Bi2O3 NPs 
Method Advantages Disadvantages Reference 
 
Sol-gel method  
 
 
 
 
 
 
 
 
Successful in 
producingBi2O3 
NPs 
• Substrate 
dependent 
• Non-uniform 
thermal 
expansion 
 
(Armelao et al., 
1998, Xiaohong 
et al., 2007) 
 
Citrate gel method (Anilkumar et al., 
2005) 
 
Thermal 
decomposition 
method 
 
High temperature (Krüger et al., 
2000) 
Flame spray 
pyrolysis method 
• Requires line of 
sight to the 
surface being 
coated 
• Difficult to 
handle 
 
(Mädler and 
Pratsinis, 2002) 
Polyol method Required alkali as 
precipitation 
reagent 
 
(Jungk and 
Feldmann, 2001) 
